All Categories

With six weeks left in the year, this newsletter should be all about getting in gear for the 2021 planning cycle. Or, maybe, it should be about Q1, JPM, and how to tell your commercial story in a nanosecond or less. Or how about gratitude, since it is almost Thanksgiving?

In the accelerated, high-stakes world of biopharma, thinking big, thinking fast, and thinking smart, isn’t just an option — it’s a priority. Why then, are we not tapping into our most educated generation and exploring what millennials have to offer? (A rhetorical question, for sure.)

Over the past several years, The NemetzGroup has worked with numerous clients to develop key aspects of their S-1 filings — coordinating with bankers, attorneys, internal staff, and many more attorneys, all with the goal of helping these companies achieve successful public offerings.

We are fortunate to work with clients of all sizes, whose products are at various stages of their life cycle. But the angst around how to achieve a successful launch is generally the same, no matter the company.

Workshops, whether in the form of a half-day strategy session, a company-wide offsite or some other configuration, have one thing in common: They represent an opportunity for a group of people to come together in real time — to establish connections, share information, generate solutions, and achieve clear objectives. When done well, they are more than just meetings — they are highly structured, interactive, rewarding, and dare I say, fun!

In just one month, life for all of us has changed dramatically. This week, we learned that the new normal would extend at least through April, probably longer.

I write this on the day the World Health Organization (WHO) has declared Covid-19 a pandemic. Like you, I am concerned for my family, friends, colleagues, and our country, let alone the world economy. Today’s e-conversation is focused on working remotely and how to succeed if that work approach is new to you.

Many years ago, when we first started working with emerging life sciences companies to provide a roadmap for the commercialization of their technologies, we began with a list of essential activities and the corresponding budget that would be required.